#USA #San Francisco #Bridge to Life #organ preservation #Hope

Bridge to Life™ Presents Groundbreaking Clinical Trial Results

Bridge to Life™ Ltd., a leading innovator in organ preservation and perfusion technology, has made a significant impact at the 2025 World Transplant Congress (WTC). Held from August 2 to August 6 in San Francisco, this prestigious congress marks a pivotal moment in the world of transplantation. It combines efforts from renowned organizations including the American Society of Transplantation (AST), the American Society of Transplant Surgeons (ASTS), and The Transplantation Society (TTS).

At this year's congress, the quintessential highlight of the event was the presentation of 12-month follow-up data from the pivotal Bridge to HOPE trial. This trial explored the clinical and economic implications of Hypothermic Oxygenated Perfusion (HOPE) in liver transplantation. The data presented underlined the technological advancements in organ preservation, which are crucial for improving patient outcomes in transplantation.

Key Presentations at WTC 2025

Several key presentations were held, showcasing the breadth of research and insights generated throughout the study. The plenary session featured a presentation titled "Comparative Analysis of Hypothermic-Oxygenated and Normothermic Machine Perfusion", which addressed the post-hoc results from the randomized Bridge to HOPE trial alongside the prospectively collected institutional outcomes. The session was led by Dr. Chase J. Wehrle from Cleveland Clinic, a young investigator awardee of ILTS 2025, emphasizing the new voice of research in the field. Scheduled for August 4, this session expected to attract significant attention from attendees.

In addition, numerous poster sessions highlighted the findings of various studies related to HOPE. One poster focused on "The Impact of Machine Oxygenated Hypothermic Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation", dissecting the stratified analysis based on donor age. This was presented on August 4 by Dr. Marco Maria Pascale from Fondazione Policlinico Universitario Agostino Gemelli in Rome, Italy. Meanwhile, another crucial contribution, comparing mitochondrial damage and functions between hypothermic and normothermic perfusion techniques, was led by Dr. Omer Faruk Karakaya from Cleveland Clinic, affirming the vital research into cellular health post-transplant.

Further oral presentations included evaluations of the economic aspects of hypothermic oxygenated perfusion in liver transplants, presented by Dr. David Axelrod, showcasing the significance of financial viability alongside health outcomes. The presentations wrapped up with noteworthy insights into the immunomodulatory effects of HOPE and its implications for pediatric liver transplantation, thus broadening the scope of HOPE's potential applications.

Symposium on HOPE

Beyond the presentations, Bridge to Life™ also sponsored a symposium scheduled for the morning of August 4, titled "Hypothermic Oxygenated Perfusion (HOPE): From Science to Clinical Impact". This event aimed to draw connections between scientific research and practical applications in clinical settings, with notable speakers including Dr. David Axelrod from the University Hospitals Cleveland Medical Center, Dr. David Foley from the University of Wisconsin, and Dr. Andrea Schlegel from Cleveland Clinic Foundation. This symposium underscores the commitment of Bridge to Life™ to enhance educational dialogue and foster innovation in the transplantation community.

About Bridge to Life™ Ltd.

Bridge to Life™ is not only a market leader but also a pioneer in developing organ preservation solutions, including flagship products such as Belzer UW®, EasiSlush®, and the hypothermic oxygenated perfusion system, VitaSmart™. With a continuous focus on improving product quality, innovation, and accessibility, the company collaborates with leading transplantation centers and organ procurement organizations worldwide, ensuring that the advancements in organ preservation technologies reach those in need.

With its commitment to improving transplantation outcomes worldwide, Bridge to Life™ is set to continue making waves in the field of organ preservation technology. As the discussions from WTC 2025 resonate within the medical community, the hopes for enhanced patient outcomes and more efficient organ preservation methods remain at the forefront of transplantation science.